Evidence map›Paper›PMID 22561965›Full record

Trial reportAmerican journal of respiratory and critical care medicine2012

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Imre Noth, Kevin J Anstrom, Sara Bristol Calvert, Joao de Andrade, Kevin R Flaherty, Craig Glazer, Robert J Kaner, Mitchell A Olman, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 9 pooled it
41.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 9 syntheses or guidelines pooled it, 462 citations in OpenAlex.

  1. Comorbidities in clinical cohorts of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020
    Pooled it
  7. Pooled it
  8. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines.European respiratory review : an official journal of the European Respiratory Society · 2014
    Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2019
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Review

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Imre NothUniversity of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637-6076, USA. inoth@medicine.bsd.uchicago.edu
Kevin J Anstrom
Sara Bristol Calvert
Joao de Andrade
Kevin R Flaherty
Craig Glazer
Robert J Kaner
Mitchell A Olman
Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)
Clinical Research Institute · USCleveland Clinic · USCornell University · USNational Jewish Health · USThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Chicago · US

Funding

Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080413 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J · 2005 to 2013
$22.6M
Novel Therapeutic Approaches in IPFU10HL080371 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARTINEZ, FERNANDO J · 2005 to 2009
$1.4M
Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080383 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KANER, ROBERT J · 2005 to 2009
$1.1M
IPF Clinical Trial Center at VanderbiltU10HL080370 · NHLBI · VANDERBILT UNIVERSITY · PI LOYD, JAMES E · 2005 to 2009
$974k
Combination Therapy in IPFU10HL080513 · NHLBI · UNIVERSITY OF CHICAGO · PI NOTH, IMRE · 2005 to 2009
$970k
Emory Clinical Research Center in IPFU10HL080543 · NHLBI · UNIVERSITY OF LOUISVILLE · PI ROMAN, JESSE · 2005 to 2009
$968k
UCLA IPF Clinical Research NetworkU10HL080411 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BELPERIO, JOHN A · 2005 to 2009
$965k
Clinical Center for an Idiopathic Pulmonary Fibrosis Cl*U10HL080509 · NHLBI · UNIVERSITY OF WASHINGTON · PI RAGHU, GANESH · 2005 to 2009
$964k
Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080685 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KING, TALMADGE E · 2005 to 2009
$936k
Novel Therapies in Idiopathic Pulmonary FibrosisU10HL080571 · NHLBI · NATIONAL JEWISH HEALTH · PI BROWN, KEVIN K · 2005 to 2009
$927k
Forging a road to personalized medicine in interstitial lung diseasesK24HL111316 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 2012 to 2017
$909k
Idiopathic Pulmonary Fibrosis Clinical Research NetworkU10HL080274 · NHLBI · MAYO CLINIC ROCHESTER · PI RYU, JAY H. · 2005 to 2009
$868k
NHLBI NIH HHS K24 HL111316NHLBI NIH HHS U10 HL080274NHLBI NIH HHS U10HL080274NHLBI NIH HHS U10 HL080370NHLBI NIH HHS U10HL080370NHLBI NIH HHS U10 HL080371NHLBI NIH HHS U10HL080371NHLBI NIH HHS U10 HL080383NHLBI NIH HHS U10HL080383NHLBI NIH HHS U10 HL080411NHLBI NIH HHS U10HL080411NHLBI NIH HHS U10 HL080413NHLBI NIH HHS U10HL080413NHLBI NIH HHS U10 HL080509NHLBI NIH HHS U10HL080509NHLBI NIH HHS U10 HL080510NHLBI NIH HHS U10HL080510NHLBI NIH HHS U10 HL080513NHLBI NIH HHS U10HL080513NHLBI NIH HHS U10 HL080543NHLBI NIH HHS U10HL080543NHLBI NIH HHS U10 HL080571NHLBI NIH HHS U10HL080571NHLBI NIH HHS U10 HL080685NHLBI NIH HHS U10HL080685
6 · The paper itself

Abstract

rationaleAnimal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.

objectivesIn a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.

methodsThis was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy. MEASUREMENTS AND MAIN

resultsThe primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater absolute decline in FVC. Due to a low probability of benefit and an increase in mortality observed in the subjects randomized to warfarin (14 warfarin versus 3 placebo deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study after 145 of the planned 256 subjects were enrolled (72 warfarin, 73 placebo). The mean follow-up was 28 weeks.

conclusionsThis study did not show a benefit for warfarin in the treatment of patients with progressive IPF. Treatment with warfarin was associated with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation.

Indexed as

AdultAgedAged, 80 and overAnticoagulantsDouble-Blind MethodFemaleHospitalizationHumansIdiopathic Pulmonary FibrosisInternational Normalized RatioMaleMiddle AgedTreatment FailureWarfarinAnticoagulantsWarfarin

Identifiers

PMID22561965
PMCPMC3400994
OpenAlexW2055609841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.